Effect of bisphosphonates on bone mineral density in liver transplant patients: A meta-analysis and systematic review of randomized controlled trials

Transplant International

Volumn 23, Issue 2, 2010, Pages 200-207

  Kasturi, Krishna S ^a   Chennareddygari, Swapna ^b   Mummadi, Rajasekhara R ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Bisphosphonates; Bone mineral density; Liver transplant; Meta analysis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; ERGOCALCIFEROL; ETIDRONIC ACID; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; BONE DENSITY; CLINICAL TRIAL; DRUG EFFECT; DRUG FEVER; DRUG WITHDRAWAL; FEMUR NECK; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; LIVER GRAFT; LUMBAR SPINE; META ANALYSIS; MYALGIA; OSTEOLYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMUR NECK; FRACTURES, BONE; HUMANS; LIVER TRANSPLANTATION; LUMBAR VERTEBRAE; MALE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 73449139449     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00976.x     Document Type: Article

References (22)

1. Crawford BA, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006 144 : 239.
2. Collier J. Bone disorders in chronic liver disease. Hepatology 2007 46 : 1271.
3. Bodingbauer M, Wekerle T, Pakrah B, et al. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 2007 7 : 1763.
4. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 1995 57 : 15.
5. Atamaz F, Hepguler S, Karasu Z, Kilic M, Tokat Y. The prevention of bone fractures after liver transplantation: experience with alendronate treatment. Transplant Proc 2006 38 : 1448.
6. Monegal A, Guanabens N, Suarez MJ, et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int 2009 22 : 198.
7. Vedi S, Ninkovic M, Garrahan NJ, Alexander GJ, Compston JE. Effects of a single infusion of pamidronate prior to liver transplantation: a bone histomorphometric study. Transpl Int 2002 15 : 290.
8. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 1998 4 : 404.
9. Dodidou P, Bruckner T, Hosch S, et al. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 2003 14 : 82.
10. Hommann M, Abendroth K, Lehmann G, et al. Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant Proc 2002 34 : 2296.
11. Pennisi P, Trombetti A, Giostra E, Mentha G, Rizzoli R, Fiore CE. Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int 2007 27 : 251.
12. Millonig G, Graziadei IW, Eichler D, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 2005 11 : 960.
13. Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 2002 37 : 93.
14. Riemens SC, Oostdijk A, van Doormaal JJ, et al. Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen. Osteoporos Int 1996 6 : 213.
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 17 : 1.
16. Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int 2006 17 : 942.
17. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003 125 : 941.
18. Karges W, Trautwein C. Liver transplantation and osteoporosis: securing "bone-fied" success. Liver Transpl 2006 12 : 1322.
19. Ruf KM, Johnson NK, Clifford T, Smith KM. Risk factors, prevention, and treatment of corticosteroid-induced osteoporosis in adults. Orthopedics 2008 31 : 768.
20. Hardinger KL, Ho B, Schnitzler MA, et al. Serial measurements of bone density at the lumbar spine do not predict fracture risk after liver transplantation. Liver Transpl 2003 9 : 857.
21. Mitterbauer C, Schwarz C, Haas M, Oberbauer R. Effects of bisphosphonates on bone loss in the first year after renal transplantation - a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006 21 : 2275.
22. Giannini S, Nobile M, Ciuffreda M, et al. Long-term persistence of low bone density in orthotopic liver transplantation. Osteoporos Int 2000 11 : 417.